845614-11-1 | Bitopertin

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$19.00	$14.00
2mg	98%	in stock	$28.00	$19.00
10mg	98%	in stock	$46.00	$33.00
100mg	95%	in stock	$160.00	$112.00
250mg	95%	in stock	$320.00	$224.00
1g	95%	in stock	$1,035.00	$724.00

Description

• Catalog Number: AH51043
• Chemical Name: Bitopertin
• CAS Number: 845614-11-1
• Molecular Formula: C21H20F7N3O4S
• Molecular Weight: 543.4550
• MDL Number: MFCD18251496
• SMILES: Fc1cc(cnc1N1CCN(CC1)C(=O)c1cc(ccc1O[C@H](C(F)(F)F)C)S(=O)(=O)C)C(F)(F)F

Computed Properties

• Complexity: 872
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 36
• Hydrogen Bond Acceptor Count: 13
• Rotatable Bond Count: 5
• XLogP3: 4

Literature

• Discovery of Novel Aminotetralines and Aminochromanes as Selective and Competitive Glycine Transporter 1 (GlyT1) Inhibitors.

  Journal of medicinal chemistry 20180913

• Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies.

  Biological psychiatry 20170701

• Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.

  The lancet. Psychiatry 20161201

• A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20140701

• Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.

  JAMA psychiatry 20140601

• Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.

  Clinical therapeutics 20121001

• Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia.

  Neuropharmacology 20120201

• Glycine transport inhibitors in the treatment of schizophrenia.

  Handbook of experimental pharmacology 20120101

• Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia.

  Journal of medicinal chemistry 20100624